Results 141 to 150 of about 740 (167)
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
New England Journal of Medicine, 2019 Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit alpha (IL3RA or CD123). Tagraxofusp (SL-401) is a CD123-directed cytotoxin consisting of human interleukin-3 fused to truncated diphtheria toxin.In this open ...
Kendra Sweet +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Clinical Journal of Oncology Nursing, 2021Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive, and often fatal hematologic malignancy. BPDCN is not a new entity, but it has been renamed and reclassified, which, in part, contributes to it being underrecognized. In 2018, tagraxofusp became the first U.S.
Allison, Morin +3 more
openaire +2 more sources
Tagraxofusp: First Global Approval
Drugs, 2019Tagraxofusp (tagraxofusp-erzs) [Elzonris™] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a truncated diphtheria toxin payload) that was developed by Stemline Therapeutics, Inc. for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
openaire +2 more sources
Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Expert Opinion on Biological Therapy, 2019Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has historically been limited by small numbers of patients in the target population. In recent years, the development of tagraxofusp (SL-401) (ELZONRIS, Stemline Therapeutics) for the treatment of adult and pediatric BPDCN has ...
Mansour Alfayez +2 more
openaire +2 more sources
Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope
Minerva Medica, 2020Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy, characterized by poor prognosis if treated with conventional therapy. Allogenic hematologic stem cell transplant can improve survival and can be curative, but it is available in a small percentage of patients given that the median age at diagnosis is 70 years.
Delia, Cangini +8 more
openaire +2 more sources